High Dose BAYA1040_Nifedipine: a Dose-comparative Study
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 352 participants.
Also called NCT01287260
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 352 participants
- Sponsor
- Registry
-
NCT01287260
-
- Other papers using this trial's data
- Nifedipine controlled-release 40 mg b.i.d. in Japanese patients with essential hypertension who responded insufficiently to nifedipine controlled-release 40 mg q.d.: a phase III, randomized, double-blind and parallel-group study
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Japan
- Registry status
- Completed
Technical summary
Registry record NCT01287260. Randomized; triple masking; primary purpose treatment. Start 2011-01 (registry gives no type); primary completion 2011-08 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- High Dose BAYA1040_Nifedipine: a Dose-comparative Study
- Condition
- Hypertension
- Intervention (Drug)
- Nifedipine (Adalat, BAYA1040)
- Intervention (Drug)
- Nifedipine (Adalat, BAYA1040)
- Lead sponsor
- Bayer
Record details
- Record id
cardio:ct-nct01287260- Content hash
d768485bce2499a7b4db6e872f2b1d0aa60570f655efd716ded3d19ef5596108